4.3 Article

Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis

Journal

HEALTH TECHNOLOGY ASSESSMENT
Volume 23, Issue 25, Pages 1-+

Publisher

NIHR JOURNALS LIBRARY
DOI: 10.3310/hta23250

Keywords

-

Funding

  1. National Institute for Health Research Health Technology Assessment programme

Ask authors/readers for more resources

Background: Current national and international guidelines on the management of heart failure (HF) recommend exercise-based cardiac rehabilitation (ExCR), but do not differentiate this recommendation according to patient subgroups. Objectives: (1) To obtain definitive estimates of the impact of ExCR interventions compared with no exercise intervention (control) on mortality, hospitalisation, exercise capacity and health-related quality of life (HRQoL) in HF patients; (2) to determine the differential (subgroup) effects of ExCR in HF patients according to their age, sex, left ventricular ejection fraction, HF aetiology, New York Heart Association class and baseline exercise capacity; and (3) to assess whether or not the change in exercise capacity mediates for the impact of the ExCR on final outcomes (mortality, hospitalisation and HRQoL), and determine if this is an acceptable surrogate end point. Design: This was an individual participant data (IPD) meta-analysis. Setting: An international literature review. Participants: HF patients in randomised controlled trials (RCTs) of ExCR. Interventions: ExCR for at least 3 weeks compared with a no-exercise control, with 6 months' follow-up. Main outcome measures: All-cause and HF-specific mortality, all-cause and HF-specific hospitalisation, exercise capacity and HRQoL. Data sources: IPD from eligible RCTs. Review methods: RCTs from the Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH/ExTraMATCH II) IPD meta-analysis and a 2014 Cochrane systematic review of ExCR (Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;4:CD003331). Results: Out of the 23 eligible RCTs (4398 patients), 19 RCTs (3990 patients) contributed data to this IPD meta-analysis. There was a wide variation in exercise programme prescriptions across included studies. Compared with control, there was no statistically significant difference in pooled time-to-event estimates in favour of ExCR, although confidence intervals (CIs) were wide: all-cause mortality had a hazard ratio (HR) of 0.83 (95% CI 0.67 to 1.04); HF-related mortality had a HR of 0.84 (95% CI 0.49 to 1.46); all-cause hospitalisation had a HR of 0.90 (95% CI 0.76 to 1.06); and HF-related hospitalisation had a HR of 0.98 (95% CI 0.72 to 1.35). There was a statistically significant difference in favour of ExCR for exercise capacity and HRQoL. Compared with the control, improvements were seen in the 6-minute walk test (6MWT) (mean 21.0 m, 95% CI 1.57 to 40.4 m) and Minnesota Living with Heart Failure Questionnaire score (mean -5.94, 95% CI -1.0 to -10.9; lower scores indicate improved HRQoL) at 12 months' follow-up. No strong evidence for differential intervention effects across patient characteristics was found for any outcomes. Moderate to good levels of correlation (R-trial(2) > 50% and p > 0.50) between peak oxygen uptake (VO(2)peak) or the 6MWT with mortality and HRQoL were seen. The estimated surrogate threshold effect was an increase of 1.6 to 4.6 ml/kg/minute for VO(2)peak. Limitations: There was a lack of consistency in how included RCTs defined and collected the outcomes: it was not possible to obtain IPD from all includable trials for all outcomes and patient-level data on exercise adherence was not sought. Conclusions: In comparison with the no-exercise control, participation in ExCR improved the exercise and HRQoL in HF patients, but appeared to have no effect on their mortality or hospitalisation. No strong evidence was found of differential intervention effects of ExCR across patient characteristics. VO(2)peak and 6MWT may be suitable surrogate end points for the treatment effect of ExCR on mortality and HRQoL in HF. Future studies should aim to achieve a consensus on the definition of outcomes and promote reporting of a core set of HF data. The research team also seeks to extend current policies to encourage study authors to allow access to RCT data for the purpose of meta-analysis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Cardiac & Cardiovascular Systems

Is blood flow restriction resistance training the missing piece in cardiac rehabilitation of frail patients? COMMENT

Tim Kambic, Borut Jug, Massimo Francesco Piepoli, Mitja Lainscak

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base

Federica Toto, Elisabetta Salvioni, Damiano Magri, Susanna Sciomer, Massimo Piepoli, Roberto Badagliacca, Arianna Galotta, Nikita Baracchini, Stefania Paolillo, Ugo Corra, Rosa Raimondo, Rocco Lagioia, Pasquale Perrone Filardi, Annamaria Iorio, Michele Senni, Michele Correale, Mariantonietta Cicoira, Enrico Perna, Marco Metra, Marco Guazzi, Giuseppe Limongelli, Gianfranco Sinagra, Gianfranco Parati, Gaia Cattadori, Francesco Bandera, Maurizio Bussotti, Massimo Mapelli, Manlio Cipriani, Alice Bonomi, Goncalo Cunha, Federica Re, Carlo Vignati, Andrea Garascia, Carlo Lombardi, Angela B. Scardovi, Andrea Passantino, Michele Emdin, Claudio Passino, Caterina Santolamazza, Davide Girola, Denise Zaffalon, Dario Vizza, Fabiana De Martino, Piergiuseppe Agostoni

Summary: This study aimed to assess the prognostic impact of moderate hyperkalemia in chronic HFrEF patients and found that it does not influence patients' outcome.

INTERNATIONAL JOURNAL OF CARDIOLOGY (2023)

Letter Medicine, General & Internal

Patient-Reported Outcome Measures in Oncology Drugs Approved by the European Medicines Agency, 2017-2021

Oriana Ciani, Michela Meregaglia, Francesco De Lorenzo, Francesco Perrone, Carmine Pinto

JAMA NETWORK OPEN (2023)

Article Medicine, General & Internal

The concurrent impact of mild cognitive impairment and frailty syndrome in heart failure

Izabella Uchmanowicz, Giuseppe Rosano, Massimo Francesco Piepoli, Ercole Vellone, Michal Czapla, Magdalena Lisiak, Dorota Diakowska, Anna Prokopowicz, Krzysztof Aleksandrowicz, Bernadetta Nowak, Marta Wleklik, Kenneth M. Faulkner

Summary: Pathological processes associated with ageing increase the risk of cognitive deficits and dementia. Frailty syndrome, also known as weakness or reserve depletion syndrome, may significantly accelerate these pathological processes in the elderly population. The co-occurrence of cognitive impairment and frailty syndrome significantly increases the risk of dementia and other adverse outcomes, including mortality, in the heart failure population.

ARCHIVES OF MEDICAL SCIENCE (2023)

Editorial Material Cardiac & Cardiovascular Systems

Focus on cardiomyopathy and heart failure

Geza Halasz, Francesco Bandera, Massimo Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Issue 30.08 focus on diabetes mellitus and cardiometabolic disorders

Geza Halasz, Francesco Bandera, Guido Giacalone, Massimo Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Review Oncology

Evaluating Barriers and Facilitators to the Uptake of mHealth Apps in Cancer Care Using the Consolidated Framework for Implementation Research: Scoping Literature Review

Vittoria Ardito, Georgi Golubev, Oriana Ciani, Rosanna Tarricone

Summary: This study aimed to explore barriers and enablers to the uptake of mHealth solutions used by patients with cancer undergoing treatment. A scoping literature review was conducted, and the Consolidated Framework for Implementation Research (CFIR) was used to guide data collection. The study found that multistakeholder co-design and testing of mHealth interventions, as well as addressing patient needs and ensuring technology interoperability, were key enablers for mHealth uptake.

JMIR CANCER (2023)

Editorial Material Cardiac & Cardiovascular Systems

Editorial comments: focus on metabolic disorders

Andrea Attanasio, Massimo F. Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Issue 30.10 focus on arterial hypertension

Gianfranci Parati, Massimo Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Editorial comments: focus on cardiovascular risk in type 2 diabetes mellitus and metabolic disorders

Andrea Attanasio, Geza Halasz, Massimo F. Piepoli

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

Article Medicine, General & Internal

A framework for the definition and interpretation of the use of in interventional trials

Oriana Ciani, Anthony M. Manyara, Philippa Davies, Derek Stewart, Christopher J. Weir, Amber E. Young, Jane Blazeby, Nancy J. Butcher, Sylwia Bujkiewicz, An-Wen Chan, Dalia Dawoud, Martin Offringa, Mario Ouwens, Asbjorn Hrobjartssson, Alain Amstutz, Luca Bertolaccini, Vito Domenico Bruno, Declan Devane, Christina D. C. M. Faria, Peter B. Gilbert, Ray Harris, Marissa Lassere, Lucio Marinelli, Sarah Markham, John H. Powers, Yousef Rezaei, Laura Richert, Falk Schwendicke, Larisa G. Tereshchenko, Achilles Thoma, Alparslan Turan, Andrew Worrall, Robin Christensen, Gary S. Collins, Joseph S. Ross, Rod S. Taylor

Summary: Interventional trials that use surrogate endpoints to evaluate treatment effects are increasingly common. However, there is currently inconsistency and lack of clarity in the definition and interpretation of surrogate endpoints. Surrogate endpoints are used as substitutes for the treatment effects on ultimate outcomes of interest. While traditionally biomarkers have been the focus of surrogate endpoint consideration, intermediate outcomes that include measures of function or symptoms can also act as surrogate endpoints. However, there is a lack of consensus among stakeholders on accepting and interpreting intermediate outcomes as surrogate endpoints. Better understanding and reporting on the use of surrogate endpoints in interventional trials is urgently needed.

ECLINICALMEDICINE (2023)

Article Multidisciplinary Sciences

A repeated cross-sectional analysis on the economic impact of SARS-CoV-2 pandemic at the hospital level in Italy

Filippo Trentini, Oriana Ciani, Elena Vanni, Simone Ghislandi, Aleksandra Torbica, Elena Azzolini, Alessia Melegaro

Summary: Italy was the first European country affected by SARS-CoV-2, and little research has been done on the economic impact of caring for COVID-19 patients. This study quantifies the additional healthcare costs for hospitalizations related to the timing and status of SARS-CoV-2 cases in Italy. The study found that the overall costs of hospitalizations increased during the pandemic, particularly for SARS-CoV-2 positive patients with non-COVID-19 related diagnoses.

SCIENTIFIC REPORTS (2023)

Correction Cardiac & Cardiovascular Systems

Heart failure: an update from the last years and a look at the near future and articles listed below (vol 9, pg 3667, 2022)

M. Riccardi, A. M. Sammartino, M. Piepoli, M. Adamo, M. Pagnesi, G. Rosano, M. Metra, S. von Haehling, D. Tomasoni

ESC HEART FAILURE (2023)

Correction Cardiac & Cardiovascular Systems

Corrigendum to: Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology (vol 29, pg 275, 2022)

Massimo F. Piepoli, Marianna Adamo, Andrea Barison, Reinaldo B. Bestetti, Jan Biegus, Michael Bohm, Javed Butler, Jonathan Carapetis, Claudio Ceconi, Ovidiu Chioncel, Andrew Coats, Maria G. Crespo-Leiro, Giovanni de Simone, Heinz Drexel, Michele Emdin, Dimitros Farmakis, Martin Halle, Stephane Heymans, Tiny Jaarsma, Ewa Jankowska, Mitja Lainscak, Carolyn S. P. Lam, Maja-Lisa Lochen, Yuri Lopatin, Aldo Maggioni, Benedetta Matrone, Marco Metra, Katharine Noonan, Ileana Pina, Eva Prescott, Giuseppe Rosano, Petar M. Seferovic, Karen Sliwa, Simon Stewart, Alicia Uijl, Ilonca Vaartjes, Roel Vermeulen, W. M. Verschuren, Maurizio Volterrani, Stephan Von Haehling, Arno Hoes

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2023)

No Data Available